Accendra Health Q2 2026 adjusted EBITDA drops to $60 million; GAAP continuing-ops net loss widens to $89 million

• Accendra Health posted a GAAP loss from continuing operations of $89 million in Q2 2026, versus a $84 million loss a year earlier.
• Adjusted EBITDA (non-GAAP) fell to $60 million from $97 million in Q2 2025.
• Free cash flow (non-GAAP) swung to a $25 million outflow from a $15 million inflow in the prior-year quarter.
• Balance sheet optimization cut total funded debt to $1.75 billion at June 30, 2026 from $2.12 billion at March 31, 2026.
• 2026 outlook: revenue of $2.45-$2.55 billion, adjusted EBITDA (non-GAAP) of $300-$320 million, free cash flow near breakeven to slightly positive.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Accendra Health Inc. published the original content used to generate this news brief on August 10, 2026, and is solely responsible for the information contained therein.